Structure-Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase
作者:Valentina Noemi Madia、Rosaria Benedetti、Maria Letizia Barreca、Liza Ngo、Luca Pescatori、Antonella Messore、Giovanni Pupo、Francesco Saccoliti、Sergio Valente、Antonello Mai、Luigi Scipione、Yujun George Zheng、Cristina Tintori、Maurizio Botta、Violetta Cecchetti、Lucia Altucci、Roberto Di Santo、Roberta Costi
DOI:10.1002/cmdc.201700040
日期:2017.8.22
Several p300 inhibitors (i.e., histone acetyltransferase inhibitors, HATis) have been described so far, but they all suffer from low potency, lack of specificity, or low cell permeability, which thus highlights the need to find more effective inhibitors. Our cinnamoyl derivative, 2,6-bis(3-bromo-4-hydroxybenzylidene)cyclohexanone (RC56), was identified as an active and selective p300 inhibitor and was
人p300是一种多面体转录共激活因子,在乙酰化特定赖氨酸残基上的组蛋白乙酰化中起关键作用。大量证据表明,p300与多种疾病有关,包括白血病,肿瘤和病毒感染。它参与多效性生物学作用和与疾病的联系为确定其调制如何代表合适的药物靶标提供了理论依据。迄今为止,已经描述了几种p300抑制剂(即组蛋白乙酰转移酶抑制剂HATis),但是它们都具有效力低,缺乏特异性或细胞通透性低的缺点,因此突出了寻找更有效抑制剂的需求。我们的肉桂酰基衍生物2,6-双(3-溴-4-羟基亚苄基)环己酮(RC56)被鉴定为一种活性和选择性的p300抑制剂,并被证明是研究与p300的构效关系的良好候选物。在这里,我们描述与我们的命中结构相关的新HAT的设计,合成和生物学评估。此外,我们通过诱导拟合对接和分子动力学模拟的方法研究了p300与最佳命中分子之间的相互作用,从而深入了解了影响其对目标酶活性的独特化学特征。